Trial Profile

A PHASE 1, RANDOMIZED, OPEN LABEL, 2 PERIOD, CROSS OVER, SINGLE DOSE STUDY TO DEMONSTRATE THE AREA UNDER THE CURVE EQUIVALENCE BETWEEN TOFACITINIB ORAL SOLUTION FORMULATION AND TABLET FORMULATION UNDER FASTED CONDITION IN HEALTHY PARTICIPANTS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Tofacitinib (Primary)
Indications Ankylosing spondylitis; Atopic dermatitis; Dermatomyositis; Diffuse scleroderma; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Pulmonary sarcoidosis; Rheumatoid arthritis; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Pfizer

08 Jan 2020 Status changed from recruiting to completed.
10 Nov 2019 Planned End Date changed from 5 Dec 2019 to 6 Dec 2019.
10 Nov 2019 Planned primary completion date changed from 7 Nov 2019 to 6 Dec 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com